PET/MRI in PAH Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03688698|
Recruitment Status : Completed
First Posted : September 28, 2018
Last Update Posted : September 28, 2018
|Condition or disease||Intervention/treatment|
|Pulmonary Arterial Hypertension||Radiation: PET/MRI|
Objectives In pilot study investigators aimed to compare novel parameters of right ventricle (RV) function from right heart catheterization (RHC) and magnetic resonance imaging (MRI) with PET-derived RV FDG uptake.
Background Right ventricular (RV) function is a major determinant of survival in patients with pulmonary arterial hypertension (PAH). Hemodynamic parameters like end-systolic elastance (Ees), arterial elastance (Ea), pulmonary arterial compliance (PAC) and Ees/Ea ratio have been shown to reflect RV function and prognosis in PAH. Increased RV 18F-fluoro-2-deoxyglucose (FDG) uptake in positron emission tomography (PET) was recently associated with progressive RV dysfunction in these patients.
Methods Twenty-five stable PAH patients (49.92±15.94 years) and twelve healthy subjects (control group, 44.75±13.51 years) had simultaneous PET and MRI scans performed. FDG was used as a tracer and its uptake was presented as a standardized uptake value (SUV) for both left (LV) and right ventricle.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||37 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||The Relationship Between Myocardial 18F-FDG Uptake and Right Ventricular Coupling Obtained by PET/MRI Hybrid Imaging in Patients With Pulmonary Arterial Hypertension.|
|Actual Study Start Date :||May 1, 2016|
|Actual Primary Completion Date :||June 1, 2017|
|Actual Study Completion Date :||January 1, 2018|
- Changes in PET/MRI parameters in PAH Patients after 2 years follow-up in case of death or clinical deterioration [ Time Frame: 2 years ]We would like to depict most significant changes in newly approved parameters from hybrid PET/MRI imaging e.g. standardised uptake value of glucose in heart, right ventricle ejection fraction, end systolic elastance, mean pulmonary pressure. This could allow us indicate possible new prognostic factors in PAH.
- Need of PAH targeted therapy escalation [ Time Frame: 2 years ]Clinical worsening of patient leading to therapy escalation.